Omeros Corp - ESG Rating & Company Profile powered by AI
The article includes a questions and answers table on Omeros Corp. If you work at Omeros Corp and you wish to use your Sustainability aseessment, please get in touch. Full Sustainability analysis of Omeros Corp are accessed by signing in.
Omeros Corp in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 0.0; made up of an environmental score of 0.0, social score of 0.0 and governance score of 0.0.
0.0
Low ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| ... | ... | ... | |
| 1967 | Hospira Inc | 0.3 | Low |
| 1967 | PRA Health Sciences Inc | 0.3 | Low |
| 1970 | Omeros Corp | 0.0 | Low |
| 1970 | CSPC Innovation Pharmaceutical Co Ltd | 0.0 | Low |
| 1970 | CTC Bio Inc | 0.0 | Low |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Omeros Corp have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Omeros Corp disclose current and historical energy intensity?
Sign up for free to unlockDoes Omeros Corp report the average age of the workforce?
Sign up for free to unlockDoes Omeros Corp reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Omeros Corp disclose its ethnicity pay gap?
Sign up for free to unlockDoes Omeros Corp disclose cybersecurity risks?
Sign up for free to unlockDoes Omeros Corp offer flexible work?
Sign up for free to unlockDoes Omeros Corp have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Omeros Corp disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Omeros Corp conduct supply chain audits?
Sign up for free to unlockDoes Omeros Corp disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Omeros Corp conduct 360 degree staff reviews?
Sign up for free to unlockDoes Omeros Corp disclose the individual responsible for D&I?
Sign up for free to unlockDoes Omeros Corp disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Omeros Corp disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Omeros Corp disclose water use targets?
Sign up for free to unlockDoes Omeros Corp have careers partnerships with academic institutions?
Sign up for free to unlockDid Omeros Corp have a product recall in the last two years?
Sign up for free to unlockDoes Omeros Corp disclose incidents of discrimination?
Sign up for free to unlockDoes Omeros Corp allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Omeros Corp issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Omeros Corp disclose parental leave metrics?
Sign up for free to unlockDoes Omeros Corp disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Omeros Corp disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Omeros Corp disclose the pay ratio of women to men?
Sign up for free to unlockDoes Omeros Corp support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Omeros Corp disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Omeros Corp reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Omeros Corp involved in embryonic stem cell research?
Sign up for free to unlockDoes Omeros Corp disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Omeros Corp disclose its waste policy?
Sign up for free to unlockDoes Omeros Corp report according to TCFD requirements?
Sign up for free to unlockDoes Omeros Corp disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Omeros Corp disclose energy use targets?
Sign up for free to unlockDoes Omeros Corp disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Omeros Corp have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Omeros Corp
These potential risks are based on the size, segment and geographies of the company.
Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers related to dysfunction of the immune system, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN) and atypical hemolytic uremic syndrome (aHUS); and Phase II clinical trial to treat COVID-19. Its clinical programs also consist of PPAR" (OMS405) that is in Phase II to treat opioid and nicotine addiction; PDE7 (OMS527), which is in Phase I trial for treating addiction and compulsive disorders, and movement disorders; and MASP-3 (OMS906) that is in Phase I trial for paroxysmal nocturnal hemoglobinuria (PNH) and other alternative pathway disorders. The company's preclinical programs comprise MASP-2-small-molecule inhibitors used for the treatment of aHUS, IgAN, HSCT-TMA, and age-related macular degeneration; longer-acting second generation antibody targeting MASP-2; and MASP-3-small-molecule inhibitors to treat PNH and other alternative pathway disorders. Its preclinical programs also include GPR174 Inhibitors and Chimeric Antigen Receptor (CAR) T-Cell and Adoptive T-Cell Therapies for various cancers; and G protein-coupled receptor targets for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular, musculoskeletal, and other disorders. The company was incorporated in 1994 and is headquartered in Seattle, Washington.